Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors

Objectives Baricitinib has shown efficacy and a favorable safety profile in randomized trials for moderate-to-severe atopic dermatitis (AD), but real-world evidence is limited. We conducted a multicenter, retrospective and prospective study aimed at evaluating the long-term effectiveness and safety...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Niccolò Gori, Lucia Di Nardo, Elena Ippoliti, Flaminia Antonelli, Luisa Boeti, Anna Balato, Eugenia Veronica Di Brizzi, Maddalena Nicoletti, Maria Esposito, Maria Concetta Fargnoli, Andrea De Berardinis, Lina Maria Magnanimi, Marco Galluzzo, Claudia Paganini, Marina Talamonti, Luca Bianchi, Maddalena Napolitano, Cataldo Patruno, Giuseppe Lauletta, Francesca di Vico, Ketty Peris
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2025-12-01
Edice:	Journal of Dermatological Treatment
Témata:	Atopic dermatitis baricitinib Janus Kinase inhibitor precision medicine
On-line přístup:	https://www.tandfonline.com/doi/10.1080/09546634.2025.2578249
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!